(HUM) Humana - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4448591028
HUM: Insurance, Medical, Pharmacy, Dental, Vision, Life
Humana Inc. (NYSE: HUM) stands as a prominent player in the U.S. health insurance sector, operating through two primary segments: Insurance and CenterWell. The Insurance segment offers a diverse range of medical and specialty insurance products, including Medicare Advantage, Medicaid, and commercial group health insurance. CenterWell focuses on healthcare services, encompassing pharmacy benefit management, home health care, and senior-focused primary care centers. This dual structure allows Humana to integrate insurance with care delivery, fostering a value-based care approach that emphasizes preventive medicine and cost efficiency.
Humanas business model is bolstered by its robust administrative platform, which supports both fully insured and self-insured plans. The company has made significant investments in digital health technologies and data analytics to enhance member engagement and improve health outcomes. With a market capitalization of over $31 billion, Humanas financial profile includes a price-to-earnings ratio of approximately 25.79 and a forward P/E of 15.36, indicating expectations of future growth. The companys strategic focus on senior demographics and government-sponsored plans positions it well in a growing market, making it a notable consideration for investors seeking exposure to the managed healthcare sector.
Additional Sources for HUM Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HUM Stock Overview
Market Cap in USD | 31,034m |
Sector | Healthcare |
Industry | Healthcare Plans |
GiC Sub-Industry | Managed Health Care |
IPO / Inception | 1993-01-22 |
HUM Stock Ratings
Growth 5y | -32.2% |
Fundamental | 12.3% |
Dividend | 46.0% |
Rel. Strength Industry | -31.2 |
Analysts | 3.62/5 |
Fair Price Momentum | 223.12 USD |
Fair Price DCF | 536.42 USD |
HUM Dividends
Dividend Yield 12m | 1.24% |
Yield on Cost 5y | 1.06% |
Annual Growth 5y | 7.20% |
Payout Consistency | 54.7% |
HUM Growth Ratios
Growth Correlation 3m | -17.8% |
Growth Correlation 12m | -64.2% |
Growth Correlation 5y | -5.3% |
CAGR 5y | -5.12% |
CAGR/Max DD 5y | -0.09 |
Sharpe Ratio 12m | -0.78 |
Alpha | -40.54 |
Beta | 0.42 |
Volatility | 32.14% |
Current Volume | 2863.1k |
Average Volume 20d | 1793.1k |
As of February 22, 2025, the stock is trading at USD 255.91 with a total of 2,863,097 shares traded.
Over the past week, the price has changed by +0.82%, over one month by -10.10%, over three months by -13.16% and over the past year by -29.60%.
Neither. Based on ValueRay Fundamental Analyses, Humana is currently (February 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 12.34 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HUM as of February 2025 is 223.12. This means that HUM is currently overvalued and has a potential downside of -12.81%.
Humana has received a consensus analysts rating of 3.62. Therefor, it is recommend to hold HUM.
- Strong Buy: 7
- Buy: 2
- Hold: 17
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, HUM Humana will be worth about 248.7 in February 2026. The stock is currently trading at 255.91. This means that the stock has a potential downside of -2.8%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 296.8 | 16% |
Analysts Target Price | 296.1 | 15.7% |
ValueRay Target Price | 248.7 | -2.8% |